This page is updated frequently with new Cytokine-related patent applications.
|Method of treating t cell mediated disorders|
A method of treating a t-cell mediated disorders in a tissue includes administering to the tissue of the subject a therapeutically effective amount of a complement antagonist that substantially reduces t-cell differentiation or t-cell inflammatory cytokine generation.. .
Case Western Reserve University
|Macrophage inhibitory cytokine-1 (mic-1) as a prognostic marker in chronic kidney disease|
The present invention relates to methods of prognosing the survival of a diseased subject, particularly a subject with chronic kidney disease (ckd), as well as selecting an end-stage renal disease subject for a kidney transplant. The methods involve detecting an elevated amount of macrophage inhibitory cytoking-1 (mid-1) in a test body sample from the diseased subject.
St Vincent's Hospital Sydney Limited
|Methods and multi-vessel renal neuromodulation|
Methods and apparatus are provided for multi-vessel neuromodulation, e.g., via a pulsed electric field. Such multi-vessel neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
|Combination therapy for the treatment of autoimmune diseases|
The present invention pertains to compounds and their combination for use in the prevention or therapy of a subject suffering from an autoimmune disease such as diabetes type 1. Provided are antagonists of t-cells that are used in combination with antagonists of the cytokine cxcl10, sequentially or concomitantly, in a subject suffering from an autoimmune disease, in particular diabetes type 1..
Fraunhofer-gesellschaft Zur Förderung Der Angewandten Forschung E.v.
The present invention provides biomatrix scaffolds, a tissue extract enriched for extracellular matrix components and bound growth factors, cytokines and hormones, and methods of making and using same.. .
The University Of North Carolina At Chapel Hill
|Defined composition gene modified t-cell products|
Aspects of the invention described herein, concern approaches to make genetically modified t-cells comprising a chimeric antigen receptor for human therapy. In some alternatives, the methods utilize a selection and/or isolation of cd4+ and/or cd8+ t-cells from a mixed t-cell population, such as, peripheral blood or apheresis derived mononuclear cells.
Seattle Children's Hospital (dba Seattle Children's Research Institute)
|Production of cytotoxic antibody-toxin fusion in eukaryotic algae|
Methods and compositions are disclosed to engineer chloroplast comprising heterologous genes encoding target binding domain fused to a eukaryotic toxin and produced within a subcellular organelle, such as a chloroplast. The present disclosure demonstrates that when chloroplasts are used, toxins normally refractive to production in eukaryotic cells may be used to produce recombinant fusion proteins with binding domains that are soluble, properly folded and post-translationally modified, where the multifunctional activity of the fusion protein is intact.
|Methods and pulsed electric field neuromodulation via an intra-to-extravascular approach|
Methods and apparatus are provided for pulsed electric field neuromodulation via an intra-to-extravascular approach, e.g., to effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, changes in cytokine upregulation and other conditions in target neural fibers. In some embodiments, the itev pef system comprises an intravascular catheter having one or more electrodes configured for intra-to-extravascular placement across a wall of patient's vessel into proximity with target neural fibers.
Medtronic Ardian Luxembourg S.a.r.i.
|Engineered cytokine- and chemokine-expressing candida albicans strains and methods of use|
Recombinant nucleic acid constructs for expression of heterologous cytokines or chemokines in c. Albicans, and genetically modified c.
Carnegie Mellon University
|Monoclonal antibodies that modulate immunity to mtb and enhance immune clearance|
The invention is directed to compositions and methods for stimulating, enhancing or modulating the immune system of a patient before or after infection by a pathogen, and in particular mtb. Compositions of the invention contain non-naturally occurring antigens that generate an effective cellular and/or humoral immune response to mtb and/or antibodies that are specifically reactive to mtb antigens.
Longhorn Vaccines And Diagnostics, Llc
Novel formulations to inhibit cyclooxygenase and pro-inflammatory cytokine mediated diseases
The invention provides method and composition for alleviating one or more symptoms associated with a medical condition mediated by one or more of a cyclooxygenase, a pro-inflammatory cytokine, and a pro-inflammatory enzyme. The method includes administering an effective amount of a composition to a person suffering from the medical condition.
Bioved Pharmaceuticals, Inc.
Compositions and methods for reducing c/ebp homologous protein activity in myeloid-derived suppressor cells
Provided are compositions and methods of use thereof that modulate c/ebp homologous stress-related protein (chop) activity in myeloid-derived suppressor cells (mdscs). Chop is a key point in the response of mdscs to tumor-generated stress factors.
Board Of Supervisors Of Louisana State University And Agricultural And Mechanical College
Compositions and methods for modulating an immune response
Described herein are compositions for increasing il-12 production comprising igg or a fragment thereof or a variant thereof and uses of said compositions for treating cancer and infectious diseases. Also described herein are compositions for decreasing il-12 production comprising an agent that inhibits signaling mediated by interaction between fcrn and igg and uses of said compositions for treating autoimmune diseases.
The Brigham And Women's Hospital, Inc.
Combination therapy for immunostimulation
The present invention relates to a method for immunostimulation in a mammal which comprises a. Administration of at least one mrna containing a region which codes for at least one antigen of a pathogen or at least one tumour antigen, and b.
Composition derived from stem cell released molecules & methods for formulation thereof
Compositions for use in treatment of a variety of tissue diseases include stem cells and stem cell released molecules (srm's) suspended in an aqueous solution with a cellulosic material or other thickening agent. The stem cells and srm's can be derived from one or more distinct cell lines.
Bioregenerative Sciences, Inc.
Method for predicting therapeutic effect of biological preparation on rheumatoid arthritis
By using at least one serum concentration selected from the group consisting of sgp130, ip-10, stnfri, stnfrii, gm-csf, il-1β, il-2, il-5, il-6, il-7, il-8, il-9, il-12, il-13, il-15, eotaxin, vegf, mcp-1, tnf-α, ifn-γ, fgf basic, pdgf-bb sil-6r and mip-1α, the therapeutic effect (improvement of symptoms and possibility of response) of an inflammatory cytokine-targeting biological preparation on a patient having rheumatoid arthritis can be predicted in any type of facility in a simple, inexpensive, and highly accurate manner before administering the biological preparation.. .
Use of an il-17/il-23 bispecific antibody for treating inflammation
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of il-17a, il-17f, and il-23. Antagonists include antibodies and antibody fragments that bind il-23 and that bind il-17a or il-17f, such as antibodies that are cross-reactive for il-17a and il-17f.
Trifunctional t cell-antigen coupler and methods and uses thereof
A trifunctional molecule comprising a target-specific ligand, a ligand that binds a protein associated with the tcr complex and a t cell receptor signaling domain polypeptide is provided. Engineering t cells with this novel receptor engenders antigen specific activation of numerous t cell functions, including cytokine production, degranulation and cytolysis..
Use of low molecular weight fractions of human serum albumin in treating diseases
The present invention provides a method of modulating various aspects of the immune system. In particular, the present invention teaches the use of diketopiperazines (dkps) to modulate various aspects of the immune system such as, for example, inflammation, t-cells and various cytokines..
Ampio Pharmaceuticals, Inc.
Method for cancer therapy based on co-administration of a parvovirus and a cytokine
Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a cytokine, preferably ifn-γ, and the use of said composition for treatment of cancer, e.g., a brain tumor.. .
Use of egg yolk oil and the benzopyrene-eliminated egg yolk oil in the treatment of allergic rhinitis
The application of egg yolk oil, as well as benzopyrene-eliminated egg yolk oil, is prepared for medicaments for the treatment of allergic rhinitis. By topical application of egg yolk oil in the nasal cavity, symptoms of allergic rhinitis could be improved significantly.
Harbin Medical University
Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
The present invention encompasses methods and compositions for the generation and use of cytotoxic t lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated t cell population and/or that employ a particular bioreactor having a gas permeable membrane..
Wilson Wolf Manufacturing
Icos binding proteins
The present invention relates to an icos binding protein or antigen binding portion thereof that is an agonist to human icos and does not induce complement, adcc, or cdc when placed in contact with a t cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said icos binding protein or antigen binding portion thereof. Further the icos binding proteins or antigen binding portions thereof of the present invention are capable of activating a t cell when placed in contact with said t cell; stimulating t cell proliferation when placed in contact with said t cell and/or inducing cytokine production when placed in contact with said t cell.
Glaxosmithkline Intellectual Property Development Limited
Cyclic dinucleotides for cytokine induction
Wherein x1 is h or f; x2 is h or f; at least one among x1 and x2 is a fluorine atom; z is oh, or1, sh or sr1, wherein: r1 is na or nh4, or r1 is an enzyme-labile group which provides oh or sh in vivo such as pivaloyloxymethyl; b1 and b2 are bases chosen from adenine, hypoxanthine or guanine, and b1 is a different base than b2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described..
Compounds targeting proteins, compositions, methods, and uses thereof
The present invention provides modulators of protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses.
Therapeutic compositions for treatment of ocular inflammatory disorders
The invention comprises a composition with means to inhibit the function of the inflammatory cytokine il-17 and methods for using this composition to treat il-17-mediated ocular inflammatory disorders. The invention also discloses devices for delivering this composition to the eye..
The Schepens Eye Research Institute, Inc.
Pharmaceutical containing dendritic cells, and producing same
[solution] the present invention relates to a pharmaceutical containing dendritic cells pulsed with α-galactosylceramide for the prevention and/or treatment of diseases in which th2-type cytokines are effective, and a method for producing the same.. .
Nanoparticle-mediated delivery of cytokines for maintenance of the regulatory t cell phenotype
Compositions for delivery of growth factors needed for stable tregs and methods of use thereof are provided. In preferred embodiments, the compositions can induce, increase, or enhance a functionally robust induced cd4 treg population (e.g., foxp3+ treg) in vivo or ex vivo.
Drug application device, detection device, drug application method, and detection method
A drug application device irradiates terahertz light onto skin, outputs information concerning detection target cytokine determined from reflected rays of the terahertz light, and supplies a drug on the basis of the output information. A detection device irradiates terahertz light onto a patch attached to skin, and outputs information concerning detection target cytokine determined from reflected rays of the terahertz light..
Seiko Epson Corporation
Novel modified curcumins and their uses
Wherein α, β, a, b, and r1-r4 are defined herein. This invention also provides pharmaceutical compositions comprising the above compounds, a method of accelerating the healing of a wound, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (mmp), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting nfκ-b activation in a population of cells..
Compositions for preserving insulin-producing cells and insulin production and treating diabetes
Nuclear transport modifiers such as csn50 and csn50.1, afford in vivo islet protection following a 2-day course of intense treatment in autoimmune diabetes-prone, non-obese diabetic (nod) mice, a widely used model of type 1 diabetes (t1d), which resulted in a diabetes-free state for one year without apparent toxicity and the need to use insulin. Csn50 precipitously reduces the accumulation of islet-destructive autoreactive lymphocytes while enhancing activation-induced cell death of t and b lymphocytes derived from nod mice.
Novel use of trimetazidine as a hepatoprotective medicine in prevention and treatment of liver diseases and conditions
This present invention discloses a new use of trimetazidine as a hepatoprotective drug in prevention and treatment of liver diseases, wherein trimetazidine is capable of inhibiting activation of resting t lymphocytes to activated lymphocytes, reducing release of cytokines, and reducing the hepatocyte injury caused by the immune system; capable of inhibiting fatty acid metabolism in hepatocytes and optimizing energy process in hepatocytes; and capable of maintaining normal function of mitochondrial permeability transition pores and reducing hepatocyte apoptosis. Clinical research and trial results suggest that, when administered to patients suffering from liver diseases and conditions, trimetazidine is capable of providing significant hepatoprotective function, and effectively decreasing transaminase levels (including alanine aminotransferase, aspartate transaminase, etc.), with such features as shortening the course of disease, reducing the mortality rate, easy and safe use, and low treatment cost.
Culture medium for hematopoeitic stem cells and the applications thereof as well as the stem cells culture method
The present invention discloses a culture medium for hematopoietic stem cells and the applications thereof as well as the stem cells culture method, which adopts amino acids, vitamins, salts, lipids, protein polypeptides and cytokines, together with one or several of trace elements, small organic molecules, hematopoietic stem cell proliferation agents, plant extracts and animal tissue cell extracts, to compose the hematopoietic stem cell culture medium, which can quickly proliferate different species of cd34+ cells, and improve both the proliferation speed and telomere length of cd34+ cells significantly; also, hematopoietic stem cells cultured in the hematopoietic stem cell culture medium described in the present invention may keep their cell functions as well, achieve the functions include but not limited to anti-tumor, anti-aging, and extending lives, thus having a pretty good application prospect.. .
China Life Science Technology Group Limited
Cytokine receptor peptides, compositions thereof and methods thereof
The invention provides a pharmaceutical composition including a peptide comprising at least a portion of a chemokine receptor or a g-protein coupled receptor and optionally a cytokine. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma.
Symthera Canada Ltd.
Methods for testing t cell priming efficacy in a subject
The present invention relates to methods for testing t cell priming efficacy in a subject. In particular the present invention relates to an in vitro method for testing t cell priming efficacy in a subject comprising the steps of a) providing sample from the subject, b) culturing the sample in a medium which induces the differentiation of dendritic cells, c) maturing the dendritic cells obtained at step a) in presence of an amount of at least one antigen and an amount of at least one cytokine or ligand suitable for the activation of a pathogen recognition receptor, d) priming and expanding the t cells present in the sample and e) analyzing the func tionality of the primed t cells..
UniversitÉ Paris - Sud
Blood derived immune stimulatory compositions
Neutrophil extracellular traps (nets) are webs of dna held together with immunogenic peptides, released by neutrophils subsequent to activation. Nets are the most potent stimulator of dendritic cells, monocytes and t cells given their ability to activate tlr3, tlr4, tlr7 and tlr9.
Batu Biologics, Inc.
Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
The present invention concerns multimeric complexes based on antibody fusion proteins comprising an ad moiety attached to the c-terminal end of each antibody light chain. The complexes further comprise effector moities attached to ddd moieties.
Ibc Pharmaceuticals, Inc.
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance.
The Johns Hopkins University
The invention provides antibodies that specifically bind to pd-l1 and fusion molecules comprising pd-l1 binding proteins constructed with an il15 receptor-binding domain, nucleic acid molecules encoding the same, and therapeutic compositions thereof. The agents inhibit pd-l1-mediated immunosuppression and enhance cell and cytokine mediated immunity for the treatment of neoplastic and infectious diseases..
Kadmon Corporation, Llc